S&P 500   4,574.22 (-1.74%)
DOW   34,488.83 (-1.84%)
QQQ   393.70 (-1.50%)
AAPL   164.00 (+2.35%)
MSFT   330.29 (-1.88%)
FB   327.24 (-3.19%)
GOOGL   2,855.50 (-1.89%)
AMZN   3,504.90 (-1.59%)
TSLA   1,136.38 (-0.05%)
NVDA   322.77 (-3.29%)
BABA   126.54 (-3.85%)
NIO   38.98 (-3.66%)
CGC   10.39 (-6.06%)
AMD   157.29 (-2.85%)
GE   95.23 (-3.22%)
MU   84.82 (-1.53%)
T   22.67 (-5.11%)
F   19.24 (-2.19%)
DIS   143.84 (-2.69%)
ACB   6.20 (-3.73%)
AMC   34.13 (-7.36%)
PFE   53.94 (+2.94%)
BA   195.63 (-1.45%)
S&P 500   4,574.22 (-1.74%)
DOW   34,488.83 (-1.84%)
QQQ   393.70 (-1.50%)
AAPL   164.00 (+2.35%)
MSFT   330.29 (-1.88%)
FB   327.24 (-3.19%)
GOOGL   2,855.50 (-1.89%)
AMZN   3,504.90 (-1.59%)
TSLA   1,136.38 (-0.05%)
NVDA   322.77 (-3.29%)
BABA   126.54 (-3.85%)
NIO   38.98 (-3.66%)
CGC   10.39 (-6.06%)
AMD   157.29 (-2.85%)
GE   95.23 (-3.22%)
MU   84.82 (-1.53%)
T   22.67 (-5.11%)
F   19.24 (-2.19%)
DIS   143.84 (-2.69%)
ACB   6.20 (-3.73%)
AMC   34.13 (-7.36%)
PFE   53.94 (+2.94%)
BA   195.63 (-1.45%)
S&P 500   4,574.22 (-1.74%)
DOW   34,488.83 (-1.84%)
QQQ   393.70 (-1.50%)
AAPL   164.00 (+2.35%)
MSFT   330.29 (-1.88%)
FB   327.24 (-3.19%)
GOOGL   2,855.50 (-1.89%)
AMZN   3,504.90 (-1.59%)
TSLA   1,136.38 (-0.05%)
NVDA   322.77 (-3.29%)
BABA   126.54 (-3.85%)
NIO   38.98 (-3.66%)
CGC   10.39 (-6.06%)
AMD   157.29 (-2.85%)
GE   95.23 (-3.22%)
MU   84.82 (-1.53%)
T   22.67 (-5.11%)
F   19.24 (-2.19%)
DIS   143.84 (-2.69%)
ACB   6.20 (-3.73%)
AMC   34.13 (-7.36%)
PFE   53.94 (+2.94%)
BA   195.63 (-1.45%)
S&P 500   4,574.22 (-1.74%)
DOW   34,488.83 (-1.84%)
QQQ   393.70 (-1.50%)
AAPL   164.00 (+2.35%)
MSFT   330.29 (-1.88%)
FB   327.24 (-3.19%)
GOOGL   2,855.50 (-1.89%)
AMZN   3,504.90 (-1.59%)
TSLA   1,136.38 (-0.05%)
NVDA   322.77 (-3.29%)
BABA   126.54 (-3.85%)
NIO   38.98 (-3.66%)
CGC   10.39 (-6.06%)
AMD   157.29 (-2.85%)
GE   95.23 (-3.22%)
MU   84.82 (-1.53%)
T   22.67 (-5.11%)
F   19.24 (-2.19%)
DIS   143.84 (-2.69%)
ACB   6.20 (-3.73%)
AMC   34.13 (-7.36%)
PFE   53.94 (+2.94%)
BA   195.63 (-1.45%)
OTCMKTS:ENZN

Enzon Pharmaceuticals Stock Forecast, Price & News

$0.38
-0.01 (-3.08%)
(As of 11/29/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.36
$0.38
50-Day Range
$0.29
$0.41
52-Week Range
$0.16
$0.85
Volume
26,800 shs
Average Volume
83,911 shs
Market Capitalization
$28.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.19
30 days | 90 days | 365 days | Advanced Chart
Receive ENZN News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Enzon Pharmaceuticals logo

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. The company was founded on September 17, 1981 and is headquartered in Cranford, NJ.

Headlines

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Short Interest Update
November 18, 2021 |  americanbankingnews.com
Enzon Pharmaceuticals (ENZN) vs. Its Rivals Critical Analysis
November 17, 2021 |  americanbankingnews.com
Contrasting Enzon Pharmaceuticals (ENZN) and Its Competitors
November 16, 2021 |  americanbankingnews.com
Critical Review: Enzon Pharmaceuticals (ENZN) and Its Rivals
November 10, 2021 |  americanbankingnews.com
Enzon Pharmaceuticals Inc (ENZN)
July 13, 2021 |  nasdaq.com
Enzo Biochem, Inc. (ENZ)
June 16, 2021 |  finance.yahoo.com
Enzon Pharmaceuticals Inc.
February 11, 2021 |  barrons.com
Enzon Pharmaceuticals Inc. Regi (EZ1.SG)
January 27, 2021 |  au.finance.yahoo.com
Enzon Pharmaceuticals Announces Results of Rights Offering
October 21, 2020 |  finance.yahoo.com
Enzon Pharmaceuticals Announces Key Dates for Rights Offering
September 15, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
OTCMKTS:ENZN
Previous Symbol
NASDAQ:ENZN
CUSIP
29390410
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$50 thousand
Book Value
$0.10 per share

Profitability

Net Income
$-1.31 million
Net Margins
-117.79%
Pretax Margin
-92.49%

Debt

Price-To-Earnings

Miscellaneous

Free Float
74,015,000
Market Cap
$28.05 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/05/2021
Today
11/30/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

0.96 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Enzon Pharmaceuticals (OTCMKTS:ENZN) Frequently Asked Questions

How has Enzon Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Enzon Pharmaceuticals' stock was trading at $0.1693 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ENZN stock has increased by 123.3% and is now trading at $0.3780.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Enzon Pharmaceuticals?

Enzon Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 14,700 shares, an increase of 818.8% from the October 31st total of 1,600 shares. Based on an average trading volume of 147,200 shares, the days-to-cover ratio is currently 0.1 days.
View Enzon Pharmaceuticals' Short Interest
.

How were Enzon Pharmaceuticals' earnings last quarter?

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) released its quarterly earnings data on Friday, November, 5th. The biotechnology company reported ($0.01) earnings per share for the quarter. Enzon Pharmaceuticals had a negative trailing twelve-month return on equity of 10.09% and a negative net margin of 117.79%.
View Enzon Pharmaceuticals' earnings history
.

Who are Enzon Pharmaceuticals' key executives?

Enzon Pharmaceuticals' management team includes the following people:
  • Richard L. Feinstein, Secretary, Chief Executive & Financial Officer

What other stocks do shareholders of Enzon Pharmaceuticals own?

What is Enzon Pharmaceuticals' stock symbol?

Enzon Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ENZN."

How do I buy shares of Enzon Pharmaceuticals?

Shares of ENZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enzon Pharmaceuticals' stock price today?

One share of ENZN stock can currently be purchased for approximately $0.38.

How much money does Enzon Pharmaceuticals make?

Enzon Pharmaceuticals has a market capitalization of $28.05 million and generates $50 thousand in revenue each year. The biotechnology company earns $-1.31 million in net income (profit) each year or ($0.04) on an earnings per share basis.

What is Enzon Pharmaceuticals' official website?

The official website for Enzon Pharmaceuticals is www.enzon.com.

Where are Enzon Pharmaceuticals' headquarters?

Enzon Pharmaceuticals is headquartered at 20 Commerce Drive Suite 135, Cranford NJ, 07016.

How can I contact Enzon Pharmaceuticals?

Enzon Pharmaceuticals' mailing address is 20 Commerce Drive Suite 135, Cranford NJ, 07016. The biotechnology company can be reached via phone at (732) 980-4500, via email at [email protected], or via fax at 732-980-4585.


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.